Side effects and treatment initiation barriers of sodium-glucose cotransporter 2 inhibitors in heart failure: a systematic review and meta-analysis.

Davor VukadinovićAmr AbdinStefan D AnkerGiuseppe M C RosanoFelix MahfoudMilton PackerJaved ButlerMichael Böhm

Published in: European journal of heart failure (2022)

Sodium-glucose cotransporter 2 inhibitor therapy is not associated with a clinically relevant risk of hypotension and volume depletion. Its use reduces the risk of AKI. This analysis supports current guideline recommendations on early use of SGLT2 inhibitors.

Keyphrases

heart failure
acute kidney injury
left ventricular
clinical practice
mesenchymal stem cells
combination therapy
cardiac resynchronization therapy
smoking cessation